Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J1MO
|
|||
| Former ID |
DIB000012
|
|||
| Drug Name |
TRX-518
|
|||
| Synonyms |
GITR monoclonal antibody (cancer/viral infection), TolerRx; Glucocorticoid-induced TNF receptor monoclonal antibody (viral infection/cancer), TolerRx; GITR mAb (IgG/iv, cancer/viral infection), TolerRx
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1/2 | [1], [2] | |
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1 | [3] | ||
| Company |
Gitr
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Activation-inducible TNFR family receptor (TNFRSF18) | Target Info | . | [4] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | TCR Signaling Pathway | |||
| Pathway Interaction Database | Downstream signaling in naï | |||
| Reactome | TNFs bind their physiological receptors | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT01239134) Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors. U.S. National Institutes of Health. | |||
| REF 4 | Immuno-oncology moves beyond PD-1. Nat Biotechnol. 2015 Jul;33(7):673-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.